spacer
home > pmps > spring 2017 > security breach
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Security Breach

Approximately 40% of all pharmaceutical products available in the US are manufactured outside of the country. It is thought that 80% of the active ingredients in drugs are made and delivered from all over the world, and these must meet the country-specific regulatory requirements of the locations in which they are going to be sold. This highlights the complexity of the industry’s supply chain.

Like many high-value commodities, pharmaceuticals are attractive to criminals – whether they are online hackers or opportunistic individuals who hijack a truck and remove its goods – with no concern whether they are life-saving drugs, prescription medication or lifestyle products.

Negating threats means thoroughly assessing your entire distribution network to determine penetration points. This can include screening vendors to ensure that they have the proper cybersecurity measures in place; scrutinising physical vulnerabilities along the route where goods can be tampered with; and identifying countries and regions with high risks for disruptions to business continuity that can potentially impact your ability to get products from point A to B.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Steve Ward serves as Vice President for the Global Intellectual Property Protection division at Pinkerton, a global provider of corporate risk management services including security consulting, investigations, executive protection, employment screening, protective intelligence and more.
spacer
Steve Ward
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

NEUWAY Pharma and Cobra Biologics collaborate to develop GMP grade Engineered Protein Capsules (EPCs) manufacturing process

International CDMO of biologics and pharmaceuticals, together with a biopharma company developing drugs for orphan diseases, announce the conclusion of a Service Agreement relating to Engineered Protein Capsules
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

Clinical Trial Supply Forum 2018

22-24 January 2018, London, UK

In the constantly changing environment of Clinical Trial Supply, cost efficiency, end to end visibility, logistics and managing complex pipelines are STILL crucial elements that need addressing!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement